Cargando…

Biomarkers in Liver Disease: Emerging Methods and Potential Applications

Detalles Bibliográficos
Autores principales:	Aithal, Guruprasad P., Guha, Neil, Fallowfield, Jonathan, Castera, Laurent, Jackson, Andrew P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2012
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3502848/ https://www.ncbi.nlm.nih.gov/pubmed/23209913 http://dx.doi.org/10.1155/2012/437508

Ejemplares similares

Metabolic Imaging in Non-Alcoholic Fatty Liver Disease: Applications of Magnetic Resonance Spectroscopy
por: Thiagarajan, Prarthana, et al.
Publicado: (2021)

MRI assessment of altered dynamic changes in liver haemodynamics following a meal challenge in compensated cirrhosis
por: Cox, Eleanor F., et al.
Publicado: (2018)

Acceptability of chronic liver disease screening in a UK primary care setting: a qualitative evaluation
por: Knight, Holly, et al.
Publicado: (2020)

In vitro models for non-alcoholic fatty liver disease: Emerging platforms and their applications
por: Ramos, Maria Jimenez, et al.
Publicado: (2021)

Variability of noninvasive MRI and biological markers in compensated cirrhosis: insights for assessing disease progression
por: Bradley, Christopher R., et al.
Publicado: (2022)

Determining a healthy reference range and factors potentially influencing PRO-C3 – A biomarker of liver fibrosis
por: Erhardtsen, Elisabeth, et al.
Publicado: (2021)

Transient Elastography in Community Alcohol Services: Can It Detect Significant Liver Disease and Impact Drinking Behaviour?
por: Subhani, Mohsan, et al.
Publicado: (2022)

Direct targeting of risk factors significantly increases the detection of liver cirrhosis in primary care: a cross-sectional diagnostic study utilising transient elastography
por: Harman, David J, et al.
Publicado: (2015)

Comparing magnetic resonance liver fat fraction measurements with histology in fibrosis: the difference between proton density fat fraction and tissue mass fat fraction
por: Bawden, Stephen James, et al.
Publicado: (2022)

Prognostic non-invasive biomarkers for all-cause mortality in non-alcoholic fatty liver disease: A systematic review and meta-analysis
por: Cianci, Nicole, et al.
Publicado: (2022)

Biomarkers of Type IV Collagen Turnover Reflect Disease Activity in Patients with Early-Stage Non-Alcoholic Fatty Liver (NAFL)
por: Lønsmann, Ida, et al.
Publicado: (2023)

Noninvasive Evaluation of Portal Hypertension: Emerging Tools and Techniques
por: Snowdon, V. K., et al.
Publicado: (2012)

Zanubrutinib-induced liver injury: a case report and literature review
por: Atallah, Edmond, et al.
Publicado: (2021)

Economic evaluation of a community-based diagnostic pathway to stratify adults for non-alcoholic fatty liver disease: a Markov model informed by a feasibility study
por: Tanajewski, Lukasz, et al.
Publicado: (2017)

Identification of high-risk subjects in nonalcoholic fatty liver disease
por: Stern, Christiane, et al.
Publicado: (2023)

The Clinical Application of Established and Emerging Biomarkers for Chronic Respiratory Diseases
por: Ambrosino, Pasquale, et al.
Publicado: (2023)

Roles and Clinical Applications of Biomarkers in Cardiovascular Disease
por: de Franciscis, Stefano, et al.
Publicado: (2016)

Roles and Clinical Applications of Biomarkers in Cardiovascular Disease 2017
por: Serra, Raffaele, et al.
Publicado: (2017)

Biomarkers in Emergency Medicine
por: Cardelli, Patrizia, et al.
Publicado: (2018)

Cohort profile: the Trivandrum non-alcoholic fatty liver disease (NAFLD) cohort
por: Chalmers, Jane, et al.
Publicado: (2019)

Drug-induced liver injury: recent advances in diagnosis and risk assessment
por: Kullak-Ublick, Gerd A, et al.
Publicado: (2017)

Reliable computational quantification of liver fibrosis is compromised by inherent staining variation
por: Astbury, Stuart, et al.
Publicado: (2021)

Emerging Biomarkers in Renal Damage
por: Ditonno, Pasquale, et al.
Publicado: (2014)

Microbiota: An Emerging Biomarker in Colorectal Cancer
por: Tsiaoussis, John, et al.
Publicado: (2021)

Emerging New Biomarkers for Cardiovascular Disease
por: Rochette, Luc
Publicado: (2022)

Statistical methods and computer applications
por: Arora, PN, et al.
Publicado: (2009)

Development and implementation of a commissioned pathway for the identification and stratification of liver disease in the community
por: Chalmers, Jane, et al.
Publicado: (2019)

Effects of an isoenergetic low Glycaemic Index (GI) diet on liver fat accumulation and gut microbiota composition in patients with non-alcoholic fatty liver disease (NAFLD): a study protocol of an efficacy mechanism evaluation
por: Al-Awadi, Amina, et al.
Publicado: (2021)

Plasma Sphingoid Base Profiles of Patients Diagnosed with Intrinsic or Idiosyncratic Drug-induced Liver Injury
por: Gai, Zhibo, et al.
Publicado: (2023)

Application and Extension of the Alcohol Recovery Narratives Conceptual Framework
por: Subhani, Mohsan, et al.
Publicado: (2023)

Emerging clinical applications of selected biomarkers in melanoma
por: Tetzlaff, Michael T, et al.
Publicado: (2015)

Emerging Biomarkers in the Era of Personalized Cancer Medicine
por: Ricciuti, Biagio, et al.
Publicado: (2019)

Emerging Complexity in the Biomarkers of Exacerbation-Prone Asthma
por: Sterk, Peter J., et al.
Publicado: (2020)

Emerging biomarkers for early diagnosis of pancreatic cancer
por: eBioMedicine
Publicado: (2022)

Therapeutic Management of Idiosyncratic Drug-Induced Liver Injury and Acetaminophen Hepatotoxicity in the Paediatric Population: A Systematic Review
por: Niu, Hao, et al.
Publicado: (2022)

Emerging applications of 3D printed microporous prosthesis in nonunion repair: mechanisms and therapeutic potential
por: Denour, Erika, et al.
Publicado: (2022)

Non-invasive biomarkers of liver fibrosis in non-alcoholic fatty liver disease
por: Basheer, Maamon, et al.
Publicado: (2023)

What is the incidence of methotrexate or leflunomide discontinuation related to cytopenia, liver enzyme elevation or kidney function decline?
por: Nakafero, Georgina, et al.
Publicado: (2021)

Microwave Imaging and Emerging Applications
por: Meaney, Paul M.
Publicado: (2012)

Hepatic elastin content is predictive of adverse outcome in advanced fibrotic liver disease
por: Kendall, Timothy J, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_63iaqg3mvg7e2ai2qcrm39nj1u